Risk factor
Strong trading liquidity
Profitability factor
Strong margins and returns
In Guru Portfolios
About
Acuity Brands, Inc. operates as a global provider of advanced lighting and building management solutions, serving markets both within North America and internationally. The company's operations are divided into two principal segments: Acuity Brands Lighting and Lighting Controls (ABL), and the Intelligent Spaces Group (ISG). The ABL division offers a comprehensive portfolio of commercial, architectural, and specialized lighting products, alongside control systems and related components, designed for a variety of indoor and outdoor applications. This segment markets its offerings under numerous well-known brands, including Lithonia Lighting, Holophane, Peerless, Gotham, Mark Architectural Lighting, Winona Lighting, Juno, Indy, Aculux, Healthcare Lighting, Hydrel, American Electric Lighting, Sunoptics, eldoLED, nLight, Sensor Switch, IOTA, A-Light, Cyclone, Eureka, Lumniaire LED, Luminis, Dark to Light, and RELOC Wiring Solutions. Its diverse customer base for lighting products spans electrical distributors, major retail home improvement chains, utility providers, national account clients, online retailers, dedicated lighting showrooms, and energy service firms. In contrast, the ISG segment focuses on sophisticated building management systems and location-aware applications, delivered through its Distech Controls, Atrius, and Rockpile Ventures brands. This includes serving system integrators, as well as end-users such as retail establishments, airports, and large corporate campuses. Established in 2001, Acuity Brands, Inc. maintains its corporate headquarters in Atlanta, Georgia.
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral on EV/EBIT
Target Price
The average target price of AYI is 404 and suggests 12.4% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation